File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oesophageal basaloid squamous cell carcinoma: A unique clinicopathological entity with telomerase activity as a prognostic indicator

TitleOesophageal basaloid squamous cell carcinoma: A unique clinicopathological entity with telomerase activity as a prognostic indicator
Authors
KeywordsBasaloid squamous carcinoma
Oesophagus
Squamous cell carcinoma
Telomerase
Issue Date2001
PublisherJohn Wiley & Sons. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/1130
Citation
Journal Of Pathology, 2001, v. 195 n. 4, p. 435-442 How to Cite?
AbstractOesophageal basaloid squamous cell carcinoma (BSCC) is uncommon and has been reported to have a worse prognosis than squamous cell carcinomas (SCCs), but this tumour has not been fully characterized. The aim of the present study was to analyse the clinicopathological features of a large cohort of patients with oesophageal BSCC treated at a single institution. The pathology of 756 primary oesophageal cancers treated between January 1989 and December 1998 was reviewed. Tumours that fulfilled the diagnostic criteria of BSCC were identified and were compared with SCC. Their expression of MIB-1, DNA ploidy, and telomerase activity were also studied. Thirty Chinese patients (25 men and five women) with BSCC were found, comprising 4% of patients with oesophageal cancer treated by surgical resection in the study period. Their median age was 67 years (range 40-78 years). Dysphagia was usually the main presenting symptom. Other concomitant malignant tumours were seen in three patients and paraneoplastic glomerulopathy in one. Five tumours were located in the upper third, 19 in the middle third, and six in the lower third. The median length was 5.8 cm (range 2-12 cm). The median MIB-1 score of BSCC was 750 (range 400-858) and was higher than that of SCC (p = 0.003). The primary tumour and metastatic BSCC were aneuploid, as detected by flow cytometric analysis in nine patients. Telomerase activity was positive in 95% (19 out of 20) of the cases analysed. The 5-year survival of patients with BSCC was 12%. Distant metastases were seen in 53% (n = 16); lung and liver were the most common sites. The median survival of patients with tumours which had a high level of telomerase activity was significantly shorter than those with low levels of telomerase activity (1 vs. 27 months) (p = 0.001). The median survival of patients with BSCC and SCC was 26 and 16 months, respectively (p = 0.3). In conclusion, BSCC has distinctive clinicopathological features and its long-term prognosis is no worse than SCC. The level of telomerase activity may have a prognostic role. Copyright © 2001 John Wiley & Sons, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/172788
ISSN
2015 Impact Factor: 7.381
2015 SCImago Journal Rankings: 4.176
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, KYen_HK
dc.contributor.authorLaw, Sen_HK
dc.contributor.authorLuk, JMen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2012-10-30T06:24:56Z-
dc.date.available2012-10-30T06:24:56Z-
dc.date.issued2001en_HK
dc.identifier.citationJournal Of Pathology, 2001, v. 195 n. 4, p. 435-442en_HK
dc.identifier.issn0022-3417en_HK
dc.identifier.urihttp://hdl.handle.net/10722/172788-
dc.description.abstractOesophageal basaloid squamous cell carcinoma (BSCC) is uncommon and has been reported to have a worse prognosis than squamous cell carcinomas (SCCs), but this tumour has not been fully characterized. The aim of the present study was to analyse the clinicopathological features of a large cohort of patients with oesophageal BSCC treated at a single institution. The pathology of 756 primary oesophageal cancers treated between January 1989 and December 1998 was reviewed. Tumours that fulfilled the diagnostic criteria of BSCC were identified and were compared with SCC. Their expression of MIB-1, DNA ploidy, and telomerase activity were also studied. Thirty Chinese patients (25 men and five women) with BSCC were found, comprising 4% of patients with oesophageal cancer treated by surgical resection in the study period. Their median age was 67 years (range 40-78 years). Dysphagia was usually the main presenting symptom. Other concomitant malignant tumours were seen in three patients and paraneoplastic glomerulopathy in one. Five tumours were located in the upper third, 19 in the middle third, and six in the lower third. The median length was 5.8 cm (range 2-12 cm). The median MIB-1 score of BSCC was 750 (range 400-858) and was higher than that of SCC (p = 0.003). The primary tumour and metastatic BSCC were aneuploid, as detected by flow cytometric analysis in nine patients. Telomerase activity was positive in 95% (19 out of 20) of the cases analysed. The 5-year survival of patients with BSCC was 12%. Distant metastases were seen in 53% (n = 16); lung and liver were the most common sites. The median survival of patients with tumours which had a high level of telomerase activity was significantly shorter than those with low levels of telomerase activity (1 vs. 27 months) (p = 0.001). The median survival of patients with BSCC and SCC was 26 and 16 months, respectively (p = 0.3). In conclusion, BSCC has distinctive clinicopathological features and its long-term prognosis is no worse than SCC. The level of telomerase activity may have a prognostic role. Copyright © 2001 John Wiley & Sons, Ltd.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/1130en_HK
dc.relation.ispartofJournal of Pathologyen_HK
dc.rightsJournal of Pathology. Copyright © John Wiley & Sons Ltd.-
dc.subjectBasaloid squamous carcinomaen_HK
dc.subjectOesophagusen_HK
dc.subjectSquamous cell carcinomaen_HK
dc.subjectTelomeraseen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAneuploidyen_US
dc.subject.meshAntibodies, Monoclonal - Immunologyen_US
dc.subject.meshAntigens, Nuclearen_US
dc.subject.meshCarcinoma, Basosquamous - Metabolism - Pathologyen_US
dc.subject.meshCarcinoma, Squamous Cell - Metabolism - Pathologyen_US
dc.subject.meshChi-Square Distributionen_US
dc.subject.meshDiploidyen_US
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_US
dc.subject.meshEsophageal Neoplasms - Metabolism - Pathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshFlow Cytometryen_US
dc.subject.meshHumansen_US
dc.subject.meshKi-67 Antigenen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshNuclear Proteins - Immunologyen_US
dc.subject.meshPolymerase Chain Reactionen_US
dc.subject.meshPrognosisen_US
dc.subject.meshProportional Hazards Modelsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshStatistics, Nonparametricen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshTelomerase - Physiologyen_US
dc.titleOesophageal basaloid squamous cell carcinoma: A unique clinicopathological entity with telomerase activity as a prognostic indicatoren_HK
dc.typeArticleen_HK
dc.identifier.emailLaw, S: slaw@hku.hken_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityLaw, S=rp00437en_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/path.984en_HK
dc.identifier.pmid11745675-
dc.identifier.scopuseid_2-s2.0-0035166704en_HK
dc.identifier.hkuros71016-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035166704&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume195en_HK
dc.identifier.issue4en_HK
dc.identifier.spage435en_HK
dc.identifier.epage442en_HK
dc.identifier.isiWOS:000172057500006-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLam, KY=7403657165en_HK
dc.identifier.scopusauthoridLaw, S=7202241293en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats